Lilly settles Zyprexa marketing suit for $1.4 billion

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co.'s guilty plea for improper marketing of Zyprexa is its second such plea in just over three years.

Indianapolis-based Lilly pleaded guilty to one violation of the Food, Drug and Cosmetic Act on Thursday and agreed to pay $1.42 billion to settle both that criminal charge as well as civil lawsuits in which it did not admit wrongdoing.

Lilly made a similar plea in December 2005 for improperly marketing its osteoporosis drug Evista in 1998 as a treatment for breast cancer. Since the settlement, in which Lilly paid $36 million, Lilly has obtained regulatory approval for Evista to treat breast cancer.

"Since that time, Lilly has taken a number of steps to build toward an industry-leading compliance program," said Lilly spokeswoman Angela Sekston.
As part of the settlement, Lilly entered into a corporate-integrity pact. Sekston added that the company has already been doing most of the actions called for in the corporate-integrity pact signed as part of the Zyprexa settlement.

Lilly has cooperated with the Justice Department's investigation since it began in 2004. The investigation also included accusations that Lilly improperly marketed Zyprexa for use in the elderly and children, and that it did so over multiple years.

However, Lilly pleaded guilty only to improperly marketing Zyprexa to elderly patients as treatment for dementia, including Alzheimer's, from September 1999 to March 2001. For this action, Lilly agreed to pay $615 million.

The rest of the settlement money will go to resolve a series of civil lawsuits brought by the Medicaid programs of the federal governments and multiple states. These suits claimed that Lilly defrauded the health program for the poor by boosting the use of Zyprexa with improper marketing.

Lilly again denied those allegations, but agreed to settle the cases without admitting wrongdoing.

The corporate-integrity agreement Lilly entered into will last five years and will include an independent third-party review organization to assess and report on Lilly's systems, processes, policies, procedures and practices.

"Every day and with every interaction we strive to operate in a responsible and compliant manner. Doing the right thing is non-negotiable at Lilly, and I remain personally committed to all of us at Lilly maintaining the highest standards of conduct," said Lilly CEO John C. Lechleiter, in a statement.

Lilly already took a charge of $1.415 billion, or $1.29 per share, in the third quarter of 2008 in anticipation of today's settlement.

In previous settlements, Lilly has paid $62 million to 32 states to settle product-liability claims about Zyprexa. Thirteen other states have sued Lilly for both product liability and Medicaid fraud related to Zyprexa. Twelve of those suits are still outstanding after Lilly settled with Alaska last year for $15 million.

Thousands of individuals have sued Lilly over Zyprexa, claiming it caused weight gain and even diabetes. Lilly has set aside $1.2 billion to settle 32,000 individual cases. Another 125 remain.

Also outstanding are suits brought by insurance companies, labor unions and pension funds. The judge in that case, Jack Weinstein, certified it as a class action in September and recommended that Lilly settle.

Zyprexa is Lilly's bestselling drug. In 2007, it recorded $4.8 billion in global sales. After the settlement news, Lilly's share price fell 70 cents in morning trading, or 1.87 percent.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. By Mr. Lee's own admission, he basically ran pro-bono ads on the billboard. Paying advertisers didn't want ads on a controversial, ugly billboard that turned off customers. At least one of Mr. Lee's free advertisers dropped out early because they found that Mr. Lee's advertising was having negative impact. So Mr. Lee is disingenous to say the city now owes him for lost revenue. Mr. Lee quickly realized his monstrosity had a dim future and is trying to get the city to bail him out. And that's why the billboard came down so quickly.

  2. Merchants Square is back. The small strip center to the south of 116th is 100% leased, McAlister’s is doing well in the outlot building. The former O’Charleys is leased but is going through permitting with the State and the town of Carmel. Mac Grill is closing all of their Indy locations (not just Merchants) and this will allow for a new restaurant concept to backfill both of their locations. As for the north side of 116th a new dinner movie theater and brewery is under construction to fill most of the vacancy left by Hobby Lobby and Old Navy.

  3. Yes it does have an ethics commission which enforce the law which prohibits 12 specific items. google it

  4. Thanks for reading and replying. If you want to see the differentiation for research, speaking and consulting, check out the spreadsheet I linked to at the bottom of the post; it is broken out exactly that way. I can only include so much detail in a blog post before it becomes something other than a blog post.

  5. 1. There is no allegation of corruption, Marty, to imply otherwise if false. 2. Is the "State Rule" a law? I suspect not. 3. Is Mr. Woodruff obligated via an employment agreement (contractual obligation) to not work with the engineering firm? 4. In many states a right to earn a living will trump non-competes and other contractual obligations, does Mr. Woodruff's personal right to earn a living trump any contractual obligations that might or might not be out there. 5. Lawyers in state government routinely go work for law firms they were formally working with in their regulatory actions. You can see a steady stream to firms like B&D from state government. It would be interesting for IBJ to do a review of current lawyers and find out how their past decisions affected the law firms clients. Since there is a buffer between regulated company and the regulator working for a law firm technically is not in violation of ethics but you have to wonder if decisions were made in favor of certain firms and quid pro quo jobs resulted. Start with the DOI in this review. Very interesting.